Back

Efficacy and safety of selexipag based triple combination targeted drug therapy in chinese patients with pulmonary arterial hypertension

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary arterial hypertension therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Xiaopei Cui

Shandong University Qilu Hospital, Jinan (China)

4 More presentations in this session

Presentation thumbnail
A real-world study on selexipag for pulmonary arterial hypertension: a single-center retrospective study
Doctor R. Asano (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.
Professor M. D'Alto (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Could we maintain the initial efficacy of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : Insights from a single-centre study
Associate Professor H. Tokgoz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Switching sildenafil to riociguat in chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty - the S2R study
Doctor T. Kam (Shatin, HK)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary arterial hypertension therapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Comparison of triple oral and triple parenteral combination therapy in pulmonary arterial hypertension
thumbnail
Congress Presentation
Could we maintain the initial efficacy of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : Insights from a single-centre study
thumbnail
Congress Presentation
Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources